false 0001434647 0001434647 2024-12-02 2024-12-02


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of Earliest Event Reported): December 2, 2024
 

 
Zevra Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 

 
Delaware
001-36913
20-5894398
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
1180 Celebration Boulevard, Suite 103,
Celebration, FL
  34747
(Address of Principal Executive Offices)
 
(Zip Code)
 
(321) 939-3416
(Registrant's Telephone Number, Including Area Code)
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instructions A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001 per share
ZVRA
The Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
 
Emerging growth company   
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐
 
 

 
 
Item 5.02          Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On December 2, 2024, in connection with organizational changes designed to accelerate its transformation into a leading rare disease company, Zevra Therapeutics, Inc. (the “Company” or “Zevra”) notified Christal M.M. Mickle, the Company’s Chief Development Officer and Co-Founder, that she would no longer serve in such role, effective as of December 6, 2024.  Pursuant to the terms of Ms. Mickle's employment agreement dated as of May 30, 2014, as amended, and subject to her timely delivering a release of claims in the Company’s favor, Ms. Mickle will receive the severance payments and other benefits provided for in the agreement. 
 
Item 7.01 Regulation FD Disclosure.
 
On December 6, 2024, Zevra Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing the matters disclosed in this report. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
 
Item 9.01          Financial Statements and Exhibits.
 
(d)
Exhibits
 
Exhibit No.
Description
99.1
104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 
 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
Zevra Therapeutics, Inc.
 
 
 
 
Date: December 6, 2024
 
By:
/s/ Timothy J. Sangiovanni
 
 
 
Timothy J. Sangiovanni, CPA
 
 
 
Senior Vice President, Finance and Corporate Controller
 
 

Exhibit 99.1

 

 

picture3.jpg

 

Zevra Therapeutics Announces Organizational Changes

 

Celebration, Fla Dec. 6, 2024 – Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on addressing unmet needs for the treatment of rare diseases, today announced organizational changes designed to accelerate its transformation into a leading rare disease therapeutics company.

 

The company announced that it is consolidating its development and scientific functions under Adrian Quartel, M.D., FFPM, Chief Medical Officer. Adrian will be responsible for clinical development, quality assurance, and regulatory and scientific affairs. As part of these changes, Christal M.M. Mickle, Chief Development Officer, and Sven Guenther, Ph.D., Chief Scientific Officer, are departing Zevra effective December 6, 2024, and December 23, 2024, respectively. The Company has also eliminated positions in chemistry, manufacturing and controls (“CMC”) and Clinical Development, consistent with the change in portfolio priorities.

 

“Transformation of our executive team is consistent with our strategic plan to focus on late-stage clinical and commercial opportunities, which we believe will better position Zevra for continued success,” said Neil F. McFarlane, Zevras President and Chief Executive Officer. “Both Christal and Sven were instrumental in the recent approval of MIPLYFFATM, and we appreciate their contributions through the many years of their service. These changes represent a significant step toward focusing our operations and strengthening them in a way that will help minimize costs. This new structure will allow us to allocate resources and personnel expediently. These changes strengthen our ability to serve patients. Our focus on rare disease remains steadfast, and we are committed to deploying our resources aligned with our 2025 Strategic Plan to achieve our vision by continuing to execute, focus, and innovate for people living with rare diseases.”

 

As previously disclosed in the November results call, the Company completed its thorough portfolio assessment and strategic plan for 2025. To further Zevra’s transformation towards becoming a leading rare disease company, Zevra has begun executing its five-year vision to create value for patients and shareholders by organizing our priorities on four key pillars: Commercial ExcellencePipeline and InnovationTalent and Culture, and Corporate Foundation. Now focused on late-stage clinical development and commercial opportunities, Zevra has discontinued its in-house drug discovery activities and will be closing its laboratory facilities in Iowa and Virginia. Future early research and development activities will be outsourced.

 

About Zevra Therapeutics, Inc.

 

Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. Our mission is to bring life-changing therapeutics to people living with rare diseases. With unique, data-driven development and commercialization strategies, the Company is overcoming complex drug development challenges to make new therapies available to the rare disease community.

 

For more information, please visit www.zevra.com or follow us on X (formerly Twitter) and LinkedIn.

 

 

 

Caution Concerning Forward-Looking Statements

 

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding upcoming events or Zevra’s participation at such events. Forward-looking statements are based on information currently available to Zevra and its current plans or expectations. They are subject to several known and unknown uncertainties, risks, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These and other important factors are described in detail in the "Risk Factors" section of Zevra’s Annual Report on Form 10-K for the year ended December 31, 2023, Zevra’s Quarterly Report for the quarter ended September 30, 2024, and Zevra’s other filings with the Securities and Exchange Commission. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Although we believe the expectations reflected in such forward-looking statements are reasonable, we cannot assure that such expectations will prove correct. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release. 

 

# # #

 

Zevra Contact

 

Nichol Ochsner 

+1 (732) 754-2545 

nochsner@zevra.com  

 

Russo Partners Contact

 

David Schull

+1 (858) 717-2310

david.schull@russopartnersllc.com

 

 

 

 
v3.24.3
Document And Entity Information
Dec. 02, 2024
Document Information [Line Items]  
Entity, Registrant Name Zevra Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Dec. 02, 2024
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-36913
Entity, Tax Identification Number 20-5894398
Entity, Address, Address Line One 1180 Celebration Boulevard
Entity, Address, Address Line Two Suite 103
Entity, Address, City or Town Celebration
Entity, Address, State or Province FL
Entity, Address, Postal Zip Code 34747
City Area Code 321
Local Phone Number 939-3416
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ZVRA
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0001434647

Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Zevra Therapeutics Charts.
Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Zevra Therapeutics Charts.